4.4 Article

Changes in Quality of Life in Parkinson's Disease: How Large Must They Be to Be Relevant?

Journal

NEUROEPIDEMIOLOGY
Volume 48, Issue 1-2, Pages 1-8

Publisher

KARGER
DOI: 10.1159/000455863

Keywords

Minimal clinically important change; Minimal clinically important difference; Receiver operating characteristic curve; Parkinson's disease; Patient reported outcomes

Funding

  1. OTKA [PD103964]
  2. Hungarian Brain Research Program [KTIA_13_NAP-A-II/10]
  3. New National Excellence Program of the Ministry of Human Capacities, Hungary
  4. Novartis
  5. GlaxoSmithKline
  6. UCB
  7. Teva Pharmaceutical Industries Ltd.
  8. Valeant
  9. Eisai
  10. Biogen
  11. TEVA
  12. Astellas
  13. Pfizer
  14. Medtronic
  15. Boehringer Ingelheim
  16. UCB, Krka
  17. Abbvie

Ask authors/readers for more resources

Background: Minimal clinically important difference (MCID) is the smallest change in an outcome, which a patient identifies as meaningful. Although the 2 most frequently applied Parkinson's disease (PD) quality of life questionnaires (the PDQ-39 and PDQ-8) provide encouragingly similar results, their MCID thresholds appear to be vastly different. Our aim was to calculate the MCID estimates for both PDQ-39 and PDQ-8 Summary Indices (PDQ-39-SI and PDQ-8-SI) by the utilization of both anchor-and distribution-based techniques. Methods: Nine hundred eighty-five paired investigations of 365 patients were included. Three different techniques were used simultaneously to calculate the MCID values. Results: First, we replicated the previously published results demonstrating how both PDQ-39-SI and PDQ-8-SI provide similar values and respond in a similar way to changes. Subsequently, we calculated the MCID thresholds. The most optimal estimates for MCID thresholds for PDQ-39-SI were -4.72 and +4.22 for detecting minimal clinically important improvement and worsening. For PDQ-8-SI, these estimates were -5.94 and +4.91 points for detecting minimal clinically important improvement and worsening respectively. Conclusions: Our study is the first one that directly compared the MCID estimates for both PDQ-39-SI and PDQ8-SI on a large pool of patients including all disease severity stages. These MICD estimates varied across PD severity. (C) 2017 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available